Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 1/20 | 1.00 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 1.00 |
| ▸ | CTSV | O60911 | 3/20 | 0.63 |
| ▸ | CTSL | P07711 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MYC | P01106 | 1/20 | 0.52 |
| ▸ | MAX | P61244 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350754 | 1.00 | ANO1 (1.00) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737120 | 0.92 | ANO1 (0.84) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737098 | 0.88 | ANO1 (0.79) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737100 | 0.84 | ANO1 (0.72) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737170 | 0.84 | ANO1 (0.72) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737203 | 0.84 | ANO1 (0.72) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737099 | 0.83 | ANO1 (0.71) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737089 | 0.82 | ANO1 (0.70) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737168 | 0.82 | ANO1 (0.70) | ANO1ANO2CTSVCTSLMAPT | |
| SCHEMBL16737171 | 0.82 | CDC25B (0.69) | ANO1ANO2CTSVCTSLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834537-B2 | Compounds as chloride channel blocking agent | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-05 | — | — | US | claimed |
| WO-2017161222-A1 | THE USE OF INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS TO PREVENT AND TREAT PRETERM LABOR, ALONE OR IN COMBINATION WITH OTHER TOCOLYTIC AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-09-21 | — | — | WO | claimed |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-05-28 | — | — | US | claimed |
| EP-4637541-A1 | DEVICE, SYSTEM AND METHOD FOR MONITORING A SITE OF INTEREST INTERNAL TO A PATIENT BODY | Exero Medical Ltd. (IL) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024134592-A1 | DEVICE, SYSTEM AND METHOD FOR MONITORING A SITE OF INTEREST INTERNAL TO A PATIENT BODY | Exero Medical Ltd. (IL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4351739-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING SWEAT PRODUCTION | Unilever IP Holdings B.V. (NL) | 2024-04-17 | — | — | EP | disclosed |
| EP-3612180-B1 | SUBSTITUTED 2-ACYLAMINO-CYCLOALKYLTHIOPHENE-3-CARBOXYLIC ACID ARYLAMIDES AS INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNEL TMEM16A | UNIV CALIFORNIA (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022258385-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING SWEAT PRODUCTION | UNILEVER IP HOLDINGS B.V. (NL) | 2022-12-15 | — | — | WO | disclosed |
| US-11358947-B2 | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210156844-A1 | TMEM16A Modulation for Diagnostic or Therapeutic Use in Pulmonary Hypertension (PH) | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-27 | — | — | US | disclosed |
| US-20200123128-A1 | SUBSTITUTED 2-ACYLAMINO-CYCLOALKYLTHIOPHENE-3-CARBOXYLIC ACID ARYLAMIDES AS INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNEL TMEM16A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-23 | — | — | US | disclosed |
| EP-3618861-A1 | TMEM16A MODULATION FOR DIAGNOSTIC OR THERAPEUTIC USE IN PULMONARY HYPERTENSION (PH) | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | disclosed |
| EP-3612180-A1 | SUBSTITUTED 2-ACYLAMINO-CYCLOALKYLTHIOPHENE-3-CARBOXYLIC ACID ARYLAMIDES AS INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNEL TMEM16A | The Regents of the University of California (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018202471-A1 | TMEM16A MODULATION FOR DIAGNOSTIC OR THERAPEUTIC USE IN PULMONARY HYPERTENSION (PH) | BAYER AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | WO | disclosed |
| WO-2018195127-A1 | SUBSTITUTED 2-ACYLAMINO-CYCLOAKYLTHIOPHENE-3-CARBOXYLIC ACID ARYLAMIDES AS INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNEL TMEM16A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-25 | — | — | WO | disclosed |
| US-9834537-B2 | Compounds as chloride channel blocking agent | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-05 | — | — | US | disclosed |
| WO-2017161222-A1 | THE USE OF INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS TO PREVENT AND TREAT PRETERM LABOR, ALONE OR IN COMBINATION WITH OTHER TOCOLYTIC AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358947-B2 | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A | TMEM161A, ANO2, TRPV6 | ANO1 9/4885ANO2 2/4885CTSV 3721/4885 |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | CACNB2, CACNB1, CACNB4 | ANO1 94/4885ANO2 87/4885CTSV 2337/4885 |
| US-20210156844-A1 | TMEM16A Modulation for Diagnostic or Therapeutic Use in Pulmonary Hypertension (PH) | TMEM109, ANO1, ANO2 | ANO1 2/4885ANO2 3/4885CTSV 3587/4885 |
| US-20200123128-A1 | SUBSTITUTED 2-ACYLAMINO-CYCLOALKYLTHIOPHENE-3-CARBOXYLIC ACID ARYLAMIDES AS INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNEL TMEM16A | TMEM161A, ANO2, TRPV6 | ANO1 9/4885ANO2 2/4885CTSV 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.